Table 4 PBSC mobilization and collection

Patient number

179

100

44

100

35

100

51

100

49

100

/

Mobilization regimen

/

 CAD

167

93

39

89

28

80

51

100

49

100

 Cyclophosphamide

12

7

5

11

7

20

0

0

0

0

G-CSF dosage

 < 0.001

 5 µg/kg bw/day

95

53

1

2

0

0

46

90

48

98

 10 µg/kg bw/day

84

47

43

98

35

100

5

10

1

2

Plerixafor application

 < 0.001

 Yes

25

14

7

16

12

34

4

8

2

4

 No

154

86

37

84

23

66

47

92

47

96

Prolonged mobilization

 Median delay, days (range)

0

(0–21)

0

(0–5)

0

(0–5)

0

(0–3)

0

(0–21)

0.785

 Patients with distinct number of days in delay

0.777^a

  0

135

75

31

70

26

74

39

76

39

80

  1

28

16

9

20

5

14

9

18

5

10

  ≥ 2

16

9

4

9

4

11

3

6

5

10

Blood count prior to first LP

 Mean leukocyte count /nl (SD)

20

(12)

21

15

27

14

17

(8)

16

(8)

 < 0.001

 Mean PB CD34⁺ cells/µl (SD)

103

(75)

116

80

80

60

111

(91)

97

(57)

0.143

First LP session

 Mean CD34⁺ cells × 10⁶/kg (SD)

8,2

(4.2)

7,6

3,6

5,8

2,8

8,8

(4,8)

9,8

(4,1)

0.004

 Mean processed blood volume, l (SD)

15,7

(3.8)

15,0

3,8

16,4

3,4

15,4

(4,2)

16,2

(3,3)

0.436

Overall PBSC collection result

 Mean CD34⁺ cells × 10⁶/kg

10,1

(2.9)

9,7

2,6

8,8

1,8

10,5

(3,5)

10,9

(3,0)

 < 0.001

 Collection failure, n (%)

3

2

2

5

0

0

1

2

0

0

0.301

LP sessions

 Median, n (range)

1

(1–3)

1

(1–3)

2

(1–3)

1

(1–3)

1

(1–3)

0.008

 Patients with distinct number of LP sessions

0.017^b

  1

110

61

25

57

14

40

34

67

37

76

  2

59

33

18

41

17

49

14

27

10

20

  3

10

6

1

2

4

11

3

6

2

4